| What's next in the pipeline. | |
| | |
MedLine Citation:
|
PMID: 18828764 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The first decade of the new millennium has been disappointing for transplant therapeutics: no new immunosuppression agents have been approved. Several high profile drugs and biologics failed the rigors of clinical trials or had disappointing preclinical results (FTY720, FK778, anti-CDI54, anti-IL15, anti-CD28, R3421). Several challenges face the industry and clinical investigators in bringing novel drugs to the clinic including the difficulty in targeting new endpoints for toxicities or chronic allograft disease since acute rejection has been reduced to below 15% as well as the Food and Drug Administration insistence of excluding the use of immunosuppression regimens embraced by the transplant community in control arms of clinical trials. Currently six new agents, 3 small molecules (ISA247, a semisynthetic analogue of cyclosporine; AEB071, a protein kinase C isoforms inhibitor; CP 690,550, a selective Janus kinase inhibitor) are in phase II trials and 3 biologics (belatacept, a second generation CTLA4Ig; efalizumab, a humanized antiCD11a [LFA1] monoclonal antibody; and alefacept, a LFA3-IgG1 fusion receptor protein) are in phase II/III clinical trials. The preclinical pipeline is not only full but promises to address previously neglected targets and fulfill unmet medical needs in transplant therapeutics. |
| | |
Authors:
|
F Vincenti; A D Kirk |
Related Documents
:
|
19416684 - Acute rolipram/thalidomide treatment improves tissue sparing and locomotion after exper... 17950444 - Constipation: evaluation and treatment of colonic and anorectal motility disorders. 15581404 - Protecting the brain: the search for a clinically effective neuroprotective drug for st... 20215414 - Antibiotics and the social history of the controlled clinical trial, 1950-1970. 22436084 - Chitosan based mucoadhesive nanoparticles of ketoconazole for bioavailability enhanceme... 16264434 - Combinatorial pharmacogenetics. |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons Volume: 8 ISSN: 1600-6143 ISO Abbreviation: Am. J. Transplant. Publication Date: 2008 Oct |
Date Detail:
|
Created Date: 2008-10-02 Completed Date: 2009-03-26 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 100968638 Medline TA: Am J Transplant Country: Denmark |
Other Details:
|
Languages: eng Pagination: 1972-81 Citation Subset: IM |
Affiliation:
|
University of California, San Francisco, Kidney Transplant Service, San Francisco, CA, USA. Flavio.Vincenti@ucsfmedctr.org |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
B-Lymphocytes
/
drug effects Biological Products / pharmacology Cell Adhesion Clinical Trials as Topic Cytokines / metabolism Drug Design Drug Industry / trends* Humans Immunosuppression / methods* Immunosuppressive Agents / chemistry, pharmacology* Models, Biological Organ Transplantation / methods, trends Reperfusion Injury United States United States Food and Drug Administration |
| Chemical | |
Reg. No./Substance:
|
0/Biological Products; 0/Cytokines; 0/Immunosuppressive Agents |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Oleoyl-oestrone inhibits lipogenic, but maintains thermogenic, gene expression of brown adipose tiss...
Next Document: The clinical impact of islet transplantation.